GRI Bio, Inc. (GRI)
| Market Cap | 3.41M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -11.96M |
| Shares Out | 1.45M |
| EPS (ttm) | -121.80 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 21,207 |
| Open | 2.390 |
| Previous Close | 2.380 |
| Day's Range | 2.300 - 2.410 |
| 52-Week Range | 2.100 - 80.360 |
| Beta | -1.24 |
| Analysts | Strong Buy |
| Price Target | 160.00 (+6,679.66%) |
| Earnings Date | May 14, 2026 |
About GRI
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company’s portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells ... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for GRI stock is "Strong Buy." The 12-month stock price target is $160.0, which is an increase of 6,679.66% from the latest price.
News
GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions
Issued claims further strengthen global intellectual property portfolio supporting immune cell modulation platform and expand strategic presence in a high-growth international market
GRI Bio CEO, Marc Hertz, Featured in Virtual Investor “What This Means” Segment
Access the “What This Means” segment here
GRI Bio Transcript: Corporate Connect Webinar Series
GRI Bio highlighted positive phase 2A results for its lead IPF program, showing safety, biomarker improvements, and potential disease-modifying effects. Plans include advancing to phase 2B and filing an IND for a lupus program, with ongoing partnership discussions.
GRI Bio to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial
– Live video webcast on Wednesday, February 11 th at 1:00 PM EST
GRI Bio Reiterates Full Year 2025 Financial Results, Strengthens Balance Sheet and Summarizes Key Recent Highlights
Company reported $8.2 million in cash and cash equivalents at December 31, 2025 and raised additional $6.5 million in gross proceeds in January 2026
GRI Bio Delivers Compelling New Phase 2a Gene Expression Data Demonstrating Improvements in Key Drivers of Fibrosis and Lung Repair in IPF
Multiple Independent Molecular Signals Converge to Validate GRI-0621 as a Potential Disease-Modifying Therapy LA JOLLA, CA, Jan. 28, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or ...
GRI Bio Announces Reverse Stock Split
GRI's common stock is expected to begin trading on a post-split adjusted basis on January 26, 2026 LA JOLLA, CA, Jan. 21, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Compan...
GRI Bio Transcript: EGM 2026
Stockholders approved both a reverse stock split amendment and a potential adjournment proposal, with voting results to be reported on Form 8-K within four business days. A quorum was established and stakeholders had an opportunity for Q&A.
GRI Bio Announces Closing of $8.0 Million Public Offering
LA JOLLA, CA, Dec. 12, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modu...
GRI Bio Announces Pricing of $8,000,000 Million Public Offering
LA JOLLA, CA, Dec. 11, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modu...
GRI Bio Announces Positive Topline Data from its Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)
Study met its primary endpoint demonstrating that GRI-0621 was well tolerated over 12 weeks of treatment, with no drug-related severe or serious adverse events and no increase in GI issues when used w...
GRI Bio Reports 6-Week Interim Lung Function Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)
No decline in lung function observed at 6-week interim analysis builds upon positive safety and biomarker data
GRI Bio Transcript: H.C. Wainwright 27th Annual Global Investment Conference
Lead program GRI-0621 is nearing Phase 2A data in IPF, with promising interim results and a robust biomarker strategy. GRI-0803 is set to enter clinical trials for lupus next year. The pipeline targets high unmet needs in fibrotic and autoimmune diseases, with strong preclinical and early clinical data supporting future growth.
GRI Bio to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
Live video webcast on Wednesday, August 20 th at 2:20 PM ET LA JOLLA, CA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing ...
GRI Bio CEO, Marc Hertz, Participates in Virtual Investor “What This Means” Segment
Access the “What This Means” segment here
GRI Bio Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference
– Video webcast now available on-demand LA JOLLA, CA, July 22, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeli...
GRI Bio Completes Enrollment in Phase 2a Study of GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)
Currently available treatments for IPF are limited to only two approved drugs that come with significant side-effects, limited patient compliance and no impact on survival
GRI Bio's GRI-0621 Demonstrates Encouraging Safety Results at Planned Interim 6-Week Analysis in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)
The Independent Data Monitoring Committee (“IDMC”) has recommended to continue the study as planned as there are no safety concerns demonstrated in the data reviewed
GRI Bio Transcript: Alliance Global Partners Healthcare Company Showcase
GRI Bio is advancing GRI-0621, an NKT cell inhibitor, in a phase 2A IPF trial with interim data showing safety and early antifibrotic signals. Top-line results are expected in Q3, and the company is exploring additional pipeline assets targeting autoimmune diseases.
GRI Bio Transcript: A.G.P.'s Virtual Healthcare Company Showcase 2025
GRI-0621, a type I invariant NKT cell inhibitor, is in phase 2a trials for IPF, with interim and top-line data expected in Q2 and Q3. Early results show safety and an antifibrotic signal. The company is also advancing a pipeline targeting other NKT cell subsets.
GRI Bio to Participate in the Virtual Investor Closing Bell Series
Live webcast on Wednesday, May 28 th at 4:00 PM ET LA JOLLA, CA, May 21, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovat...
GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase
Live webcast fireside chat with Marc Hertz, PhD, Chief Executive Officer on Wednesday, May 21 st at 2:40 PM ET
GRI Bio Reports First Quarter 2025 Financial Results and Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interim Data in Q2 2025 and Topline Data in Q3 2025
Positive interim 2-week safety and biomarker results from its ongoing Phase 2a study evaluating GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (“IPF”)
GRI Bio's Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)
The Independent Data Monitoring Committee (IDMC) has recommended to continue the study as planned as there are no safety concerns seen in the data reviewed
GRI Bio Continues to Drive Enrollment in Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)
Enrollment completed for the 6-week interim analysis with 24 of the 36 planned patients now enrolled Company on track to report interim biomarker data from the first 12 patients imminently Completion...